drugset / Trial / NCT00325793

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

NCT00325793

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.

Timeline

Start
2004-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicardipine Small molecule Intravenous

Indications